Category Archives: Lung cancer

Impact of EML4-ALK Variants on resistance

Posted on June 15, 2018 by admin

As of April 20, 2018 Study of 2 groups of patients. Group A = 129 patients, Group B = 577 patients. The most frequent variants were Variant 1 (43%) and Variant 3 (40%). “ALK resistance mutations were significantly more common … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

Liquid Biopsy can be used to track evolution of resistance

Posted on June 15, 2018 by admin

As of January 23, 2018 and March 29, 2018: Plasma genotyping by Next Generation Sequencing (Liquid Biopsy) can be used to track evolution of resistance to various ALK inhibitors. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5785105/ https://www.ncbi.nlm.nih.gov/pubmed/29599410

Posted in Lung cancer, Research | Leave a comment

FDA approves alectinib (Alecensa) as 1st line treatment

Posted on June 15, 2018 by admin

As of November 6, 2017 FDA approves alectinib (Alecensa) as 1st line treatment based on Phase 3 results. The estimated median Progression Free Survival (PFS) for patients taking alectinib was 25.7 months, compared with 10.4 months for those taking crizotinib. The … Continue reading →

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Phase 1 & 2 full results for Lorlatinib

Posted on June 15, 2018 by admin

As of Oct. 16, 2017 Pfizer presented a Press release associated with a presentation at IASLC on Phase 2 results for 275 patients. All following are for ALK+ patients except where Ros1 is indicated Treatment Naive:  ORR 90%; IC-ORR 75% Prior … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects | Leave a comment

Great page with very high quality info on AlK & AlK inhibitors

Posted on June 16, 2017 by admin

Below is a link to a page that provides comprehensive regularly updated info written by two ALK research oncologists Dr. Alice Shaw and Ben Solomon, Phd (then edited by three people). It is written for an audience of doctors and … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments | Leave a comment

Roche at ASCO with Alectinib findings

Posted on June 6, 2017 by admin

Roche (Genentech) announced on June 6, 2017 at the 2017 ASCO conference that the have results from their first line Phase 3 Global Trial that Alectinib had a median PFS of 25.7 months vs 10.4 months for Crizotinib (over a … Continue reading →

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Zykadia (ceritinib) by Novartis is approved for first line use in US

Posted on June 6, 2017 by admin

As of May 26, 2017 the FDA approved ceritinib for first line use. So it will go head to head with crizotinib. One article said a similar EU approval was likely “in coming weeks”. The results are based on the … Continue reading →

Posted in Brain metastases, ceritinib - Zykadia from Novartis, Lung cancer, Potential Treatments, Regulatory applications & approvals, Research | Leave a comment

FDA approves brigatinib

Posted on June 6, 2017 by admin

On April 28, 2017 the FDA granted Takeda (formerly Ariad) approval for Alunbrig (brigatinib) to be sold in the US to patients who are resistant to Crizotinib.

Posted in AP26113 - brigatinib from Ariad, Lung cancer, Potential Treatments, Regulatory applications & approvals | Leave a comment

Lorlatinib granted breakthrough therapy status

Posted on June 6, 2017 by admin

On April 27, 2017, the FDA granted Pfizer Breakthrough Status on lorlatinib for patients previously treated with one or more ALK inhibitors. So you don’t have to take Crizotinib first, any of the other 3 will do. Also a Phase … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment

Clinical Trial of PLB1003 by Beijing Pearl Biotechnology

Posted on June 6, 2017 by admin

As of April 19, 2017 ClinicalTrials.gov lists a phase 1 trial of PLB1003 which targets ALK. At this time the trial is at one site: Shanghai Chest Hospital. To qualify you must have one measurable met in the body. The … Continue reading →

Posted in Lung cancer, PLB1003 - Beijing Pearl Biotechnology, Potential Treatments, Research | Leave a comment